http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003073652-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745 |
| filingDate | 2001-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1db0d540627f5f26f62262b9b0a09a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e963a324533c61afeed0a79b6eebae1 |
| publicationDate | 2003-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003073652-A1 |
| titleOfInvention | Ex-vivo and in vivo factor XII gene therapy for hemophilia A and B |
| abstract | Bypass activity for hemophilia A and B can be generated by natural or recombinant Factor VIIa. Factor XIIa when implanted into a guinea pig or monkey also facilitates the conversion of endogenous factor VII to VIIa, thereby providing bypass activity. Additionally, certain modified versions of Factor XII are known to be intrinsically active, with properties like Factor XIIa. Administration of unencapsulated Factor XIIa to a guinea pig causes a transient increase in plasma bypass activity. A continuous source of Factor XIIa, as provided by a gene therapy, is therapeutic for both Hemophilia A and B. There are three ways to provide for gene therapy. In each case, the gene for Factor XII (or Factor XIIa) can be introduced into the cell by the usual means, including, but not limited to, as naked DNA, as a DNA/lipid mixture, or as part of a viral vector system. In one manifestation, cells can be transfected with full length or modified versions of Factor XII, ex-vivo, and allowed to continuously express versions of recombinant Factor XII from unencapsulated recombinant cells implanted in the body of the patient. A second mechanism would require encapsulating the cells within the body. As a third mechanism of introducing Factor XIIa into the patient, full length or modified versions of the gene for human Factor XII can be directly administered in vivo. The advantage is provision of a universal gene therapy for hemophilia A and B, rather than separate gene therapies involving either Factor VIII (Hemophilia A) or Factor IX (Hemophilia B). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016191746-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018516571-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019205473-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10214731-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7321513-B2 |
| priorityDate | 2000-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 537.